FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Inhibrx's Trailing 12-Month Free Cash Flow is $-222.10 Mil, and Market Cap is $901.83 Mil. Therefore, Inhibrx's FCF Yield % for today is -24.63%.
The historical rank and industry rank for Inhibrx's FCF Yield % or its related term are showing as below:
INBX'
s FCF Yield % Range Over the Past 10 Years
Min: -27.44 Med: -11.18 Max: -3.73
Current: -24.63
During the past 7 years, the highest FCF Yield % of Inhibrx was -3.73%. The lowest was -27.44%. And the median was -11.18%.
INBX's FCF Yield % is ranked worse than 61.75% of 1553
companies
in the Biotechnology industry
Industry Median: -14.22
vs INBX: -24.63
The historical data trend for Inhibrx's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Inhibrx's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx's FCF Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Inhibrx's FCF Yield % falls into.
Inhibrx FCF Yield % Calculation
FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Inhibrx's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Inhibrx FCF Yield % Related Terms
Thank you for viewing the detailed overview of Inhibrx's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBX has been successfully added to your 